Across TCGA pan-cancer cohorts, KRT39 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KRT39 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher KRT39 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRT39 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, HNSC, and UCEC are the cancer types where KRT39 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
HNSC	DFS	Median	III,IV	0.100	0.683	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.623	.018	8	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KRT39 tumor-vs-normal RNA expression · all KRT39 data types